Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,650 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07394062Recruiting
Comparing chemo-immunotherapy combinations for advanced lung cancer
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
AnkaraAges 18 years+ - NCT07434518Recruiting
Study of adebrelimab for advanced small cell lung cancer
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
ShanghaiAges 18–100 - NCT07483112Recruiting
Fiber supplement study for advanced lung cancer patients
This trial tests whether adding a fiber supplement to standard immunotherapy can help treat advanced non-small cell lung cancer. It's for people whose tumors have high PD-L1 levels and no treatable genetic mutations.
BaselAges 18 years+ - NCT07559019RecruitingPhase 1
Safety study of BI115 for advanced small cell lung cancer
This early-stage trial tests a new immunotherapy drug called BI115 in people with advanced small cell lung cancer (a fast-growing type of lung cancer). The study will check if the drug is safe and whether it helps slow or shrink the cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT07224464Recruiting
Sarah Nanotechnology System for advanced solid tumors using heat therapy
This trial tests a new nanotechnology system that uses controlled heat to treat advanced solid tumors in the chest or abdomen that have not responded to standard treatments. It may be an option if you have few remaining choices and want to explore a novel approach.
Rochester, MinnesotaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT06228209Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether adding a palliative care specialist to your regular care team can improve your quality of life if you have advanced heart failure or advanced lung or certain gastrointestinal cancers. It is for people who have been in the hospital recently and live in Manhattan.
New York, New YorkAges 18 years+ - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT06247605RecruitingPhase 3
Study of AL8326 for advanced small cell lung cancer
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
Changchun, JilinAges 18 years+ - NCT06419179Enrolling by invitationPhase 2
Maintenance therapy for HRD-positive small-cell lung cancer
This trial tests whether a combination of two medications, durvalumab and olaparib, can help keep your extensive-stage small-cell lung cancer from coming back after standard first-line treatment. It is for people whose tumors have a specific genetic feature called HRD.
Cologne, North Rhine-WestphaliaAges 18–120 - NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Anchorage, AlaskaAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT05155033RecruitingPhase 2
A trial of PD-1 plus aldesleukin for melanoma or kidney cancer
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
Bethesda, MarylandAges 18–120
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,650 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.